Search

Your search keyword '"Bustreo S"' showing total 3 results
Start Over Author "Bustreo S" Database OpenAIRE
3 results on '"Bustreo S"'

1. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534

Author

Cremolini, C, Loupakis, F, Masi, G, Lonardi, S, Granetto, C, Mancini, Marialaura, Chiara, S, Moretto, R, Rossini, Daniela, Vitello, S, Allegrini, G, Tonini, G, Bergamo, F, Tomasello, G, Ronzoni, M, Buonadonna, A, Bustreo, S, Barbara, C, Boni, Maria Luisa, and Falcone, A. 1. 5.

Published
2016

3. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer

Author

Bacigalupo, A., Balcet, V., Bustreo, S., Corvò, R., Iotti, C., Lastrucci, L., Munoz, F., Musu, A., Piva, C., Riccardo Ragona, Rampino, M., Reali, A., Ricardi, U., Russi, E., and Schena, M.

Subjects
Bridged-Ring Compounds, Male, Maximum Tolerated Dose, Remission Induction, Antibodies, Monoclonal, Cetuximab, Chemoradiotherapy, Induction Chemotherapy, Middle Aged, Antibodies, Monoclonal, Humanized, Survival Rate, Treatment Outcome, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Feasibility Studies, Humans, Female, Taxoids, Fluorouracil, Cisplatin, Aged, Follow-Up Studies, Neoplasm Staging
Abstract

To determine the potential activity and tolerability of sequential treatment in head and neck cancer, we conducted a phase II trial based on induction chemotherapy of two cycles of taxotere, cisplatin and 5-fluorouracil followed by radiotherapy plus weekly cetuximab.Thirty-six patients with stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx were treated and evaluated for response and acute toxicity.Eighty-one percent of patients had stage IV disease and 42% had hypopharyngeal and oral cavity primaries. The overall response rate was 81.8%, with 60.6% complete response and 33.3% partial response. Severe toxicities were febrile neutropenia (6%) during induction chemotherapy and dermatitis (48%), mucositis (33%) and dysphagia (12%) during the concurrent phase.Our protocol proved to be feasible, effective and well tolerated. This sequential strategy should be further investigated.

Catalog

Books, media, physical & digital resources
See catalog results